NEW YORK – A team led by researchers at the Massachusetts Institute of Technology has developed a method that measures dysregulated protease activity for the early detection of lung cancer.
Detailed in a paper published last week in Science Translational Medicine, the test is one of several protease-based diagnostics developed by the MIT team, which in 2015 spun out a company, Glympse Bio, to commercialize the technology.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.